Most Popular

Methotrexate to Prevent RA, Clear as Mud

Save

Intervention in individuals predisposed to develop rheumatoid arthritis (RA), with a holy grail of prevention of RA, has long been a hot topic.

Phase 2b Study of Ianalumab in Sjögren's

Save

Ozempic will change rheumatology

Save

Ozempic is everywhere. Even all the way in Australia, where we have highly constrained supply that makes headlines and substantial limits on direct-to-consumer advertising, somehow I know the jingle from the American ad for Ozempic.

Shifting Trends in Initial RA Treatment Approaches

Save

A recent study by Sparks et al (Abstract #0509) reveals evolving trends in disease-modifying antirheumat

RIP to Glucocorticoids in GPA

Save

For many years glucocorticoids were the mainstay of our treatment of granulomatosis with polyangiitis (GPA). The paradigm shifted with cyclophosphamide and then again with rituximab, and we used less steroids, but we still used lots.

Say Goodbye to Methotrexate in PMR?

Save

For decades, glucocorticoids (GCs) have formed the backbone of polymyalgia rheumatica (PMR) management.

RA-ILD in the Spotlight at ACR 2024

Save

Over the past 5 years, there has been growing interest in RA-ILD due to its relative prevalence and severity. This seems to be one of the few RA outcomes not improving much, even with the advent of expanded treatment options. There is also a shocking lack of trial data.

Is Your Practice Up to Date? New Guidelines for SLE Nephritis

Save

Randomized controlled trials (RCTs) drive guidelines; guidelines drive clinical practice.

Novel and Emerging Therapies in Psoriatic Arthritis

Save

Recent advancements in targeted therapies, including selective inhibitors of key inflammatory pathways, offer promising outcomes for patients with active psoriatic arthritis (PsA). At ACR 2024, there have been further developments in novel therapies in PsA.

Maximizing DMARDs to Strive for Steroid-Free Remission in RA

Save

In 1950, three scientists were awarded the Nobel Prize for their groundbreaking discovery of steroids, heralded at the time as a "miracle cure" for rheumatoid arthritis (RA).

ACR 2024 - Day 3 Report

Save

Highlights from Day 3 at ACR24 included the plenary session presentation on Nipocalimab (previously reviewed), but the big highlight was the Lupus Nephritis guideline recommendations.

2024 Updated ACR Guideline for the Diagnosis and Treatment of Lupus Nephritis

#ACR Best 2024 - Day 4

Save

Although the last day of ACR Convergence 2024 was but a half day - it was chock full of gems, many coming from the late breaking abstracts presented today.  As chosen by the RheumNow faculty, here are some highlight presentations you need to know about.

What Lies Beneath: Understanding Nailfold Capillaroscopy

Save

Capillaroscopy is a non-invasive imaging technique used for the in vivo assessment of the microcirculation.

ORAL Surveillance - Is Statin Use the Problem/Solution?

Save

The findings from ORAL Surveillance Study have been a dominant conversation at recent ACR Convergence, with the seminal findings and subsequent analyses a target of debate.

Beyond the Needle: Redefining the Assessment of Lupus Nephritis

Save

Lupus nephritis is one of the most silent and severe manifestations of systemic lupus erythematosus (SLE). When not captured early, patients are at high risk of progressing to end-stage renal disease, which would require dialysis or transplantation.

ACR24: Rheumatology Roundup

Save

Join Drs. Jack Cush and Artie Kavanaugh as they review 15+ presentations and abstracts from the 2024 ACR Convergence meeting in Washington, DC. 

ACR 2024 - Day 1 Report

Save

ACR Convergence 2024 opened today with a full slate of presentations, posters and specialty meetings.  The meeting began with a flip: the plenary sessions started at 9AM and the poster session began at 1030 AM. Below are some of the highlights from day one in Washington, DC.  Anoth

ACR24 Preview Podcast (11.15.2024)

Save

ACR 2024 starts tomorrow. Here are a few previews of abstracts to be presented, along with my recommendations of sessions you don’t want to miss.

Previews:

#ACR 2024 BEST Abstracts from Day 1

Save

The RheumNow faculty have parked at the plenaries, trafficked the posters and have been finding the best the meeting offers on the first day at ACR 2024 in Washington, DC.  Here are some of the best abstracts from Saturday Nov. 16th.

Evaluation of Bimekizumab in PsA

Save

At last year’s ACR, I shared about the early clinical trial data on bimekizumab in psoriatic arthritis. Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A and F.